Genomic Health Announces Availability of Oncotype DX® Prostate Cancer Test with Potential to Triple the Number of Patients Who Can Confidently Choose Active Surveillance and Avoid Side Effects of Invasive Treatments

Groundbreaking Results from University of California, San Francisco (UCSF) Clinical Validation Study Presented at American Urological Association (AUA) Annual Meeting
First-of-its-Kind, Biopsy-Based Test Developed and Validated in Seven Studies Including More Than 1,100 Patients

Genomic Health, Inc. (GHDX) is making its Oncotype DX® prostate cancer test available to physicians and their patients today following the presentation by the University of California, San Francisco (UCSF) of a positive clinical validation study at the 2013 American Urological Association (AUA) Annual Meeting in San Diego. 

Genetic Technologies Executes Agreement With Nationwide Provider Network

Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE), is pleased to advise that it has executed an agreement with Three Rivers Provider Network, Inc. of Chula Vista, California, USA.

Three Rivers Provider Network ("TRPN") claims to be the largest supplemental PPO Network Foundation in the US, providing healthcare benefits to more than 10 million members, at more than 1 million locations nationwide.

The agreement with TRPN is the fifth such credentialing agreement executed between the Company and similar U.S. Preferred Provider Organisations ("PPOs") and increases the total number of covered lives, for which its BREVAGen™ test could be adjudicated as "in-network," to more than 23 million.

CombiMatrix Reports Preliminary Quarterly Growth in Prenatal Testing Volumes of 124% for First Quarter

CombiMatrix Corporation (CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it expects to report record volumes of prenatal testing in the first quarter ended March 31, 2013. Preliminary quarterly growth rates of 124 percent over the first quarter of 2012 were achieved for billable prenatal tests.

The continued rapid growth in prenatal testing is the result of CombiMatrix's strategic shift in mid-2012 to focus its commercial resources primarily on the prenatal molecular diagnostic testing markets, where the Company believes that chromosomal microarray analysis (CMA) is becoming the standard of care.

GenMark Diagnostics Reports Fourth Quarter and Year End 2012 Results

GenMark Exceeds 2012 Revenue Guidance; 2012 Sales Top $20 million

• Quarterly Reagent Revenue Grows 404% and Annual Reagent Revenue Grows 367%
• Installed Base Grows to 297 Analyzers
• Quarterly Gross Margin Reaches 50% and Annual Gross Margin Reaches 43%
• Annuity Per Analyzer Increased to $143,000
• FY 2013 Revenue Guidance at $35 Million

GenMark Diagnostics, Inc. (GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported financial results for the fourth quarter and year ended December 31, 2012.